Fiscal year 2025 executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.
Each company listed discloses ETON in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named ETON in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Sean Brynjelsen | $712,433 | $0 | $936,052 | $893,712 | $354,792 | $0 | $17,500 | $2,914,489 |
| President and Chief Executive Officer | ||||||||
| James Gruber | 460,460 | 0 | 336,388 | 321,172 | 171,982 | 0 | 108,066 | 1,398,068 |
| Chief Financial Officer | ||||||||
| David Krempa | 460,460 | 0 | 336,388 | 321,172 | 171,982 | 0 | 104,743 | 1,394,745 |
| Chief Business Officer | ||||||||
| Ipek Erdogan-Trinkaus | 402,722 | 0 | 0 | 0 | 150,417 | 0 | 22,153 | 575,292 |
| Chief Commercial Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Sean Brynjelsen | $2,914,489 | $2,411,923 | — | +502,566 |
| James Gruber | 1,398,068 | 1,075,080 | — | +322,988 |
| David Krempa | 1,394,745 | 1,325,083 | — | +69,662 |
| Ipek Erdogan-Trinkaus | 575,292 | 775,488 | — | −200,196 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
No insider equity transactions reported since the proxy statement.
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Sean Brynjelsen | RSA | — | — | — | 1,000,000 | — | — |
Grant-level vehicle detail not disclosed.
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Sean Brynjelsen | Option | 237,593 | 4.42 | — |
| Sean Brynjelsen | RSU | 72,004 | — | 1,217,588 |
| David Krempa | RSU | 31,566 | — | 533,781 |
| Sean Brynjelsen | RSU | 27,500 | — | 465,025 |
| James Gruber | RSU | 25,876 | — | 438,563 |
| David Krempa | RSU | 25,876 | — | 438,563 |
| James Gruber | RSU | 10,000 | — | 169,100 |
| David Krempa | RSU | 10,000 | — | 169,100 |
| Ipek Erdogan-Trinkaus | RSU | 6,020 | — | 101,798 |
| James Gruber | Option | 78,367 | 4.42 | — |
| Sean Brynjelsen | Option | 82,841 | 13 | — |
| Sean Brynjelsen | Option | 102,195 | 3.47 | — |
| James Gruber | Option | 29,771 | 13 | — |
| James Gruber | Option | 29,192 | 3.47 | — |
| James Gruber | Option | 25,000 | 3.81 | — |
| Ipek Erdogan-Trinkaus | Option | 56,250 | 12.46 | — |
| David Krempa | Option | 29,771 | 13 | — |
| David Krempa | Option | 78,367 | 4.42 | — |
| David Krempa | Option | 21,666 | 3.47 | — |
| David Krempa | Option | 6,595 | 3.78 | — |
The company aims to motivate employees to achieve short- and long-term results in the best interests of stockholders by aligning executive interests with stockholders through stock ownership and performance-based compensation. Compensation decisions consider market comparables, individual performance, and the company's ability to attract and retain qualified talent.
| CEO STI target (% of salary) | — |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Radford, an Aon company |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | true |
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2024 | 2024-06-11 | 9,170,839 | 553,043 | 63,364 | 94.31% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.
| Meeting year | Meeting date | Approval — company's computation |
|---|---|---|
| 2024 | 2024-06-11 | 94.31%a |
a. Voting standard not stated in the filing.
Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Norbert G. Riedel, Ph.DIndependent · Board Chair · Audit · Compensation · Nominating and Corporate Governance (Chair) | $123,672 | — | $194,375 | — | — | $318,047 |
| Norbert G. RiedelIndependent · Audit · Compensation | 123,672 | — | 194,375 | — | — | 318,047 |
| Paul V. MaierIndependent · Audit (Chair) · Compensation · Nominating and Corporate Governance | 83,468 | — | 194,375 | — | — | 277,843 |
| Charles J. CasamentoIndependent · Audit · Compensation (Chair) · Nominating and Corporate Governance | 80,764 | — | 194,375 | — | — | 275,139 |
| Jenn AdamsIndependent · Audit · Compensation · Nominating and Corporate Governance | 72,652 | — | 194,375 | — | — | 267,027 |
| Sean E. BrynjelsenEmployee director | — | — | — | — | — | 0 |
| Annual cash retainer | $50,000 |
|---|---|
| Annual equity retainer | $194,375 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 15,000 / 15,000 / 15,000 |
| Stock ownership guideline | — |
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $484,228 |
| Equity awards (grant-date value) | $0 |
| All other compensation | $0 |
| Total cost of the board | $484,228 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Eton Pharmaceuticals | 2025 | Sean Brynjelsen | $712,433 | $936,052 | $893,712 | $354,792 | $2,914,489 |
Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.
| # | Supports | Document | Filed | Accession | Location in document |
|---|---|---|---|---|---|
| 1 | Section 01, Sean Brynjelsen | DEF 14A | 2026-04-24 | 0001437749-26-013313 | Section “Executive Compensation”. As printed: 2,914,489. Filing ↗machine: r2 · c25 · span 259102–259111 |
| 2 | Section 01, James Gruber | DEF 14A | 2026-04-24 | 0001437749-26-013313 | Section “Executive Compensation”. As printed: 1,398,068. Filing ↗machine: r5 · c25 · span 269716–269725 |
| 3 | Section 01, David Krempa | DEF 14A | 2026-04-24 | 0001437749-26-013313 | Section “Executive Compensation”. As printed: 1,394,745. Filing ↗machine: r8 · c25 · span 280314–280323 |
| 4 | Section 01, Ipek Erdogan-Trinkaus | DEF 14A | 2026-04-24 | 0001437749-26-013313 | Section “Executive Compensation”. As printed: 575,292. Filing ↗machine: r11 · c25 · span 291771–291778 |
| 5 | Section 03, Sean Brynjelsen RSA | DEF 14A | 2026-04-24 | 0001437749-26-013313 | Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 302333–302342 |
| 6 | Section 08, Norbert G. Riedel, Ph.D | DEF 14A | 2026-04-24 | 0001437749-26-013313 | Section “Director Compensation”. As printed: 318,047. Filing ↗machine: span 141104–141111 |
| 7 | Section 08, Norbert G. Riedel | DEF 14A | 2026-04-24 | 0001437749-26-013313 | Section “Director Compensation”. As printed: 318,047. Filing ↗machine: span 141104–141111 |
| 8 | Section 08, Paul V. Maier | DEF 14A | 2026-04-24 | 0001437749-26-013313 | Section “Director Compensation”. As printed: 277,843. Filing ↗machine: span 139256–139263 |
| 9 | Section 08, Charles J. Casamento | DEF 14A | 2026-04-24 | 0001437749-26-013313 | Section “Director Compensation”. As printed: 275,139. Filing ↗machine: span 137420–137427 |
| 10 | Section 08, Jenn Adams | DEF 14A | 2026-04-24 | 0001437749-26-013313 | Section “Director Compensation”. As printed: 267,027. Filing ↗machine: span 135577–135584 |
| 11 | Section 08, Sean E. Brynjelsen | DEF 14A | 2026-04-24 | 0001437749-26-013313 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 12 | Section 06, 2024 vote | Form 8-K | 2024-06-11 | 0001437749-24-019953 | Item 5.07 · say-on-pay result. As reported: 94.31% (votes for as printed: 9,170,839). Filing ↗ |
| 13 | Section 01 trend, Δ column (computed) | Computed | — | computed | Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1) |
| 14 | Section 09b board cost (computed) | Computed | — | computed | Cash 484,228 + equity 0 + all other 0 = 484,228, summed across the director compensation table rows.machine: formula: Σ = 484,228 |
| 15 | Eton Pharmaceuticals (subject), Section 10b CEO total | DEF 14A | 2026-04-24 | 0001437749-26-013313 | CEO total compensation as printed in Eton Pharmaceuticals's own proxy. As printed: 2,914,489. Filing ↗machine: r2 · c25 · span 259102–259111 |